Medical Dermatology Specialists Phoenix — Phoenix, Arizona

Medical Dermatology Specialists Phoenix is a clinical research site located in Phoenix, Arizona, United States 85006.

Crixeo Clinical Trials Trust Score: 18/100 (FAILING). This profile has not yet been claimed by the site owner.

Medical Dermatology Specialists Phoenix has participated in 9 clinical trials with 5 currently active.

Therapeutic areas: Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Lichen Planus, Hidradenitis Suppurativa (HS).

Sponsors: Regeneron Pharmaceuticals, Incyte Corporation, Boehringer Ingelheim.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Phoenix

Browse all research sites in Arizona · View every site in Phoenix

Sponsor Feasibility Report

Trust Score: 18/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Medical Dermatology Specialists Phoenix?

Medical Dermatology Specialists Phoenix has a Crixeo Trust Score of 18/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Medical Dermatology Specialists Phoenix conducted?

Medical Dermatology Specialists Phoenix has 9 clinical trials on record, with 5 currently active. Their work covers Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Lichen Planus, Hidradenitis Suppurativa (HS).

Is Medical Dermatology Specialists Phoenix accredited by Crixeo Clinical Trials?

Medical Dermatology Specialists Phoenix has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Medical Dermatology Specialists Phoenix?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.